Cardiovascular Drugs Market (By Drug Type: Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs, Others; By Disease Indication: Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others; By Route of Administration: Oral, Parenteral, Others; By Drug Classification; By Mode of Purchase; By End Users) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030


The global cardiovascular drugs market size was valued at USD 155.6 billion in 2021 and is expected to reach around USD 231.7 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 4.52% between 2022 and 2030.

Cardiovascular Drugs Market Size 2022 To 2030

Key Takeaways:

  • By type, anticoagulants segment was reached revenue share of about 43% in 2021.
  • The antihyperlipidemic drug type segment exhibited 15.6% revenue share in 2021.
  • North America region has garnered revenue share of around 38% in 2021.

With the increasing prevalence of cardiovascular diseases among the people a rapid growth has been seen in the cardiovascular drugs market. The number of people suffering with cardiovascular diseases has tremendously increased as a result of the faulty lifestyle practices and sedentary habits of the people. The alterations in the food and drinking habits of the people too has shown a significant impact on the cardiovascular system.

The problems of cardiovascular diseases has also increased due to the rise in work pressure and stress among the people belonging to the younger generation. The people belonging to the geriatric age group already present a number of cardiovascular disorders which helps to boost the market of the cardiovascular drugs tremendously. Even minor alterations in the rhythm or rate of the cardiovascular system helps the cardiovascular drugs market to grow considerately. Not only the elderly people but also the younger generation present a number of cardiovascular complaints as a result of their lifestyle practices. With the prevalence of cardiac arrest among the people, the market for the cardiovascular drugs has boosted tremendously.

The high court associated with the use of advanced technology and medicines in the market for the cardiovascular drugs has seen or drop in the developing nations, where the disposable income of the people is very low. The developed nations possess a high disposable income which helps the market to record a higher revenue return from them. Lack of awareness among the people regarding healthcare facilities that are available for the common people lead to delay in the treatment of life-threatening conditions of the patients with cardiovascular disorders.

The occurrence of the covid 19 pandemic had shown a considerable impact on the growth of the market as a result of the restricted movements and constant lockdowns imposed by the governments worldwide. Hence, the hospitals faced a shortage of general patients presenting cardiovascular complaints. Also, with a view to avoid further risk of cross infection to the people, hospitals opted for elective procedures and checkups which hampered the regular follow-ups and checkup routines of the patients. This had a direct impact on the cardiovascular drugs market.

Moreover, the occurrence of the pandemic did benefit the cardiovascular drugs market, as a result of the increased cardiovascular complications due to the covid infection which led to clotting disorders in the patients. These complications increased the sales and supply-chain of the cardiovascular drugs market and thus facilitated its growth. With the shortage of medical facilities created due to the corona crisis had hampered the demand and supply chain of the market. Though, the supply was somehow completed as essential services were allowed to be transported. Lack of transportation facilities had hampered the growth of the market tremendously. These factors proved to be a challenge to the growth of the market during the covid crisis.

Report Scope of the Cardiovascular Drugs Market

Report Coverage Details
Market Size in 2022

USD 162.64 Billion

Market Size by 2030

USD 231.7 Billion

Growth Rate from 2022 to 2030 CAGR of 4.52%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Drug Type, Disease Indication, Route of Administration, Drug, Mode of Purchase, End Users, Geography
Companies Mentioned

Bristol-Myers Squibb Company, Bayer AG, Pfizer Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Merck & Co., AstraZeneca, Sanofi, Gilead Sciences, Inc., F. Hoffmann-La Roche


Growth Factors

  • The huge number of patients suffering with cardiovascular diseases has helped the market to record a considerable growth during the forecast period.
  • The increasing prevalence of cardiac arrest and cardiac arrhythmias has boosted the demand for cardiovascular drugs in the society.
  • The sedentary lifestyle practices have increased the prevalence of obesity among the people which directly hampers the heart health of the individual. Thus, the demand for cardiovascular drugs keeps increasing with the growing number of cardiovascular disorders.
  • The faulty food habits of the people as a result of rapid modernization have also proved to be a major factor for the number of patients suffering with cardiovascular blockages and irregularities.

The occurrence of the pandemic has also helped the market to record a considerable growth as a result of increasing cardiovascular disorders among the people. With the increasing prevalence of restricted moments in the world, the cardiovascular health of the people has deteriorated to a great extent. Lack of moment and physical activity among the people belonging to the walking class has proved to be a growing factor for the cardiovascular drugs market.

Another factor that helps the market to show a significant growth is the habit-forming nature of the drugs, which does not allow the consumer to discontinue the medications for a considerably long period of time. This keeps the revenue generation system running without interruptions. Rapid increase in the amount of stress and frustration among the people as a result of working from home has also created a number of cardiovascular diseases.

The prevalence of hypertension among the people has put an additional chance of cardiovascular disorders which helps to boost the market for the cardiovascular drugs. The long working hours which are followed by the youngsters belonging to the developing countries has increased the risk of cardiovascular disorders among them. A huge number of people are seen to be suffering with cardiovascular irregularities which increases the sales and supply of the related drugs. A drawback for the patient is that these cardiovascular in drugs cannot be easily discontinued which in turn proves to be a growing factor for the cardiovascular drugs market.

The various complications and side effects that are associated with these cardiovascular drugs help to increase the sales and demand of the other accessory drugs that are required to manage and balance these side effects. The cardiovascular drugs being an essential necessity for the people, finds its place in the disposable income of an individual which keeps the revenue return running under all circumstances. The minimum age for a cardiovascular disorder has reduced tremendously which makes it a very profitable situation for the growth of the market.

Blood thinning drugs to find a special place among all this as it goes hand in hand with the cardiovascular drugs. Lack of awareness among the people regarding their health conditions also proves to be a risk factor for the patient which creates severe pathological changes in the cardiovascular system. This leads to various cardiovascular disorders that facilitates the consumption of these drugs. These multiple reasons prove to be the growth factors for the cardiovascular drugs market.

Drug Type Insights

On the basis of drug type, the antihypertensive drugs have dominated the segment as it is the most common disorder that people are seen suffering with as a result of the high amount of salt intake and age-related disorders. The increasing stress among the people as a result of work and frustration has also increased its prevalence in the society.

Cardiovascular Drugs Market Share, By Drug Type, 2021 (%)

These drugs form a habit among the consumers which makes them purchase these drugs again and again, thus boosting the market size over the period of time. The prevalence of cholesterol has increased the use of antihyperlipidemic drugs which shows a rapid growth. Anticoagulants forms the next segment which too records a considerable growth as a result of increasing prevalence of cardiac arrest among the people.

Disease Indication Insights

On the basis of disease indication, hypertension has dominated the segment as it is the most common disease that people are seen suffering with as a result of the high work pressure among the youngsters and the age-related disorders which are caused in the geriatric population. Lack of physical activity also gives rise to a number of diseases. Higher intake of fast foods and salt has increased the prevalence of hypertension.

Heavy consumption of alcohol too leads to the causation of this cardiovascular disorder which is commonly seen among the people. Arrhythmias and hyperlipidemia form the next segment as a result of the sedentary lifestyle practices of the people and faulty lifestyle practices. CAD forms the next segment which also contributes considerably to the growth of the market.

End Users Insights

On the basis of end user, the hospital pharmacies record the highest growth as a result of the rapid demand and supply of cardiovascular drugs seen due to the easy availability of rare and commonly used drugs. The emergency cardiovascular drugs are easily available in the hospital pharmacies which are very costly and find their place in the hospitals only.

Retails stores form the next segment which shows the fastest growth as a result of its easy accessibility to the common people. Online stores too show a considerable growth with the increasing trend of online shopping. The demand for contactless delivery services of drugs has boosted the demand for cardiovascular drugs through online stores which also provides a wide range of lucrative discounts and offers to the consumers in order to attract them. The availability of a ready comparison between the other available drugs also helps the consumer to make a suitable choice of drugs.

Cardiovascular Drugs Market Share, By Region, 2021 (%)

Regions Revenue Share in 2021 (%)
North America 38%
Asia Pacific 22%
Europe 28%
Latin America 8%
MEA 4%


Geography Insights

The North American market has shown the highest growth as a result of the high prevalence of cardiovascular diseases among the people. With the growing modernization and increased trend of fast food the prevalence of hypertension and other cardiac diseases have increased. The sedentary lifestyle practices followed by the people which is clubbed with faulty food habits has increased the chances of cardiovascular diseases which boosts the demand for these drugs.

The Asia-Pacific region has also shown a considerable growth as a result of the huge population suffering from cardiovascular disorders. The increasing demand for cardiovascular drugs has boosted the economy of the market to a great extent. The European nations too have showcased a significant growth due to the high prevalence of cardiovascular disorders among the people.

Recent Developments

  • In October 2019- The FDA disclosed the approval granted regarding the addition of a disease indication which related to the prevention against the occurrence of VTE in acutely sick medical patients who were hospitalized, at risk. Thromboembolic complications were noticed in them. But no high risk was announced regarding bleeding,  for rivaroxaban which is a Janssen Pharmaceutical product.
  • In January 2019- Natco Pharma which is an Indian company disclosed the introduction of valsartan-sacubitril, which is a cardiovascular drug used in the management of congestive heart failure. The patent is held by Novartis AG in India under the name Vymada for valsartan-sacubitril.
  • In February 2019- Blackstone’s Life Sciences and Novartis AG disclosed the introduction of Anthos Therapeutics in order to develop cardiovascular drugs.

Key market players

  • Bristol-Myers Squibb Company
  • Bayer AG
  • Pfizer Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis AG
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche 

Segments covered in the report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Drug Type

  • Antihypertensive
  • Anticoagulants
  • Antihyperlipidemic
  • Antiplatelet Drugs
  • Others

By Disease Indication

  • Hypertension
  • Coronary Artery Disease
  • Hyperlipidaemia
  • Arrhythmia
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Drug Classification

By Mode of Purchase

By End Users

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

 By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the current size of cardiovascular drugs market?
The global cardiovascular drugs market size was accounted at USD 155.6 billion in 2021 and it is expected to reach around USD 231.7 billion by 2030.
The global cardiovascular drugs market is poised to grow at a CAGR of 4.52% from 2022 to 2030.
The major players operating in the cardiovascular drugs market are Bristol-Myers Squibb Company, Bayer AG, Pfizer Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Merck & Co., AstraZeneca, Sanofi, Gilead Sciences, Inc., F. Hoffmann-La Roche
The increasing number of people in the geriatric age group has boosted the sales and demand of the cardiovascular drugs. The increasing number of chronic diseases among the people has boosted the sales and demand for cardiovascular drugs.
North America region will lead the global cardiovascular drugs market during the forecast period 2022 to 2030.
  • Report Code:2037
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample